Trial Profile
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs 122-0551 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Therapeutics Incorporated
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2012 New trial record